NOS2 and myeloid sarcoma: We also detected that the C/C homozygote (Crude OR 3.070; 1.880–5.011 95% CI; p < 0.001) and the C allele (Crude OR 2.101; 1.501–2.941 95% CI; p < 0.001) of the c.1832C > T—NOS2 SNP were associated with an elevated risk of MS, while the heterozygote (Crude OR 0.492; 0.288–0.841 95% CI; p < 0.05), the T/T homozygote (Crude OR 0.369; 0.187–0.727 95% CI; p < 0.001) and the T allele (Crude OR 0.476; 0.340–0.666 95% CI; p < 0.001) of the same polymorphism were associated with a decreased risk of this disease (Table 1).